Applying Ocado, the UPC grants a R262 request to access CFI documents

No items found.
​
July 9, 2025

NJOY Netherlands B.V v Juul Labs International, Inc (UPC_CFI_309/2023)

Order issued 9 June 2025 (ORD_27305/2025) [1]

The Paris Central Division revoked Juul Lab's patent EP 3 498 115 B1 by decision dated 5th November 2024 (UPC CFI 309 /2023). [2] Juul Labs subsequently appealed the decision, and while the appeal remains pending, a firm of lawyers and patent attorneys ("the Applicant") lodged a request under Rule 262.1(b) on 21 February 2025 to access pleadings and evidence in the first instance proceedings. Juul Labs requested that the Court rejects the request, and alternatively, if the Court does grant the request, it should grant access only with a restriction ‘from filing the written pleadings or parts of them with other courts or judicial instances.'

The Law

Rule 262.1(b) states that written pleadings and evidence lodged at the Court and recorded by the Registry shall be available to the public upon ‘reasoned request' to the Registry; the decision is taken by the judge-rapporteur after consulting the parties. A ‘reasoned request' is one where an applicant explains why their access to the specified documents is necessary and legitimate. A party to the litigation may request that certain information in written pleadings or evidence be kept confidential and provide specific reasons for such confidentiality.

The Court of Appeal in Ocado v Autostore (UPC_CoA_404/2023)[3] expanded on Rule 262, finding that when there is a request made by a member of public to access court documents, the interests of a member of the public must be weighed against the interests mentioned in Articles 10 and 45 UPCA. Articles 10 and 45 govern the general principle that first instance and appeal proceedings shall be open to the public unless the Court decides to make them confidential, to the extent necessary, in the interest of one of the parties or other affected persons, or in the general interest of justice or public order.

The Applicant's interest

The Applicants' interest is one of access to precedent. As a German IP firm, they submit that they represent various clients in revocation proceedings before the UPC which have ‘comparable subject matter' to the first instance decision. For this reason, they argue their request is justified because they intend to obtain a ‘comprehensive picture of the line of arguments that led to the Court's decision' (para 3.7).

The Defendant's interest

Juul Labs argued that, despite their claim to represent other UPC parties in revocation cases with ‘comparable subject matter,' the Applicant has no legitimate interest in the subject matter of the present case. Juul Labs alleged that the Applicant would likely ‘copy-paste' extracts from the written pleadings and evidence to reproduce into EPO oppositions or other court proceedings, leading to third party access of such material without lodging a reasoned request with the UPC, thereby contravening the interests of the parties and the UPCA principles to keep relevant materials confidential.

Decision

Per Ocado v Autostore, the Court must undergo a weighing of the balance of interests. The Court found that the Applicant had submitted a reasonable request; their intention to obtain a greater understanding of the arguments that led to the Court's decision was justifiable. The Court did not find Juul Labs' arguments to be capable of shifting the balance of interest towards withholding the case documents, and the Court found their denouncement of the Applicant's legitimate interest insufficient. Juul Labs' concerns about the potential misuse of documents in other jurisdictions were also dismissed. The Court clarified that the general position as found in Articles 10 and 45 is that ‘the register is public and proceedings are open to the public, unless the balance of interest involved is such that they are to be kept confidential' (para 4.4). Quoting Ocado v Autostore (para 50), the Court clarified that withholding access to documents once a judgment has been published no longer serves the purpose of protecting the integrity of proceedings, as the publicly available decision will contain the relevant arguments and evidence presented by the parties and thus already subject to public debate.

The Court granted the Applicant access to written pleadings and evidence, with appropriate redaction of personal data. However, the Court also granted Juul Labs leave to appeal and suspended the effects of the order until the deadline for filing an appeal, or if an appeal is filed, until the end of the appeal proceedings.

Written by Dalton Tucker and Fathia Adeniran.

[1] https://www.unified-patent-court.org/en/node/125754

[2] https://www.unified-patent-court.org/en/node/1239

[3] https://www.unified-patent-court.org/en/node/657

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
The UPC After Three Years: From Experiment to Enforcement Forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
Inside the Visser AI Launch Party
20 May 2026
EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.